Form 4: EXAS CEO Conroy Reports RSU Vesting, Tax Withholding

Exact Sciences CEO Kevin T. Conroy reported the vesting of restricted stock units and subsequent tax-related share dispositions, increasing his direct beneficial ownership.

Summary

• Kevin T. Conroy, President and CEO of Exact Sciences Corp., reported multiple transactions on February 27, 2026.
• He acquired a total of 68,097 shares of common stock through the vesting of restricted stock unit (RSU) awards (18,143, 22,168, and 27,786 shares respectively).
• In connection with these vestings, 32,007 shares were disposed of by Exact Sciences for tax withholding purposes at a price of $103.25 per share.
• Following these transactions, Mr. Conroy directly beneficially owns 1,278,045 shares of common stock.
• His total reported beneficial ownership on this Form 4, including indirect holdings, is 1,557,821 shares.
• He also holds an additional 737,129 vested and unvested options and restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices and scheduled vesting of equity awards, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units represents a planned compensation event for the CEO, aligning his interests with long-term shareholder value.
• The increase in direct beneficial ownership of common stock by the CEO demonstrates continued confidence in the company.

Negatives

• A portion of the vested shares was sold to cover tax obligations, which is a standard practice but results in a reduction of the total shares received.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled vesting of future restricted stock unit installments.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing RSU vesting and tax-related sales, are common for executives in publicly traded companies across the biotechnology and diagnostics industry. These transactions reflect pre-planned compensation structures and are generally not indicative of new strategic shifts or market-moving events, unlike filings from competitors reporting significant open-market purchases or sales.

Related Party Transactions

• The vesting of restricted stock units and subsequent tax withholding transactions involve the company's President and CEO, Kevin T. Conroy, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The increase in the CEO's direct beneficial ownership aligns executive interests with shareholder value, while the tax-related sales are a routine part of equity compensation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Future installments of the restricted stock unit awards are scheduled to vest annually on the last trading day of February.

Key Dates

Keywords

Exact Sciences, EXAS, Kevin T. Conroy, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Share Ownership, Tax Withholding